{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:35Z","timestamp":1794020015688,"version":"4.8.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy typically characterized by anemia, thrombocytopenia, and end-organ injury. aHUS occurs due to endothelial injury resulting from overactivation of the alternative pathway of the complement system. The etiology of the dysregulated complement system is either a genetic mutation in 1 or more complement proteins or an acquired deficiency due to autoantibodies. Over the past decade, advancements in our understanding of the role of complement in the pathophysiology of aHUS as well as the availability of anticomplement drugs has been a game-changer for our patients. These drugs have revolutionized the clinical course, outcome, and prognosis of this disease. Therefore, all patients in whom aHUS is suspected should undergo testing for complement genetic variants and autoantibodies. In approximately 30% to 40% of patients, a genetic variant of uncertain significance (VUS) may be identified. Such patients should undergo further testing to define the significance of the VUS. A combination of antigenic, functional, and biomarker analyses can assist in establishing the significance of the variants and thereby define the etiology in most patients. These analyses will also help to determine the duration of treatment based on the individual's genetic alteration. This review aims to shed light on the diagnosis and management of aHUS and discusses how to stratify patients to determine who can safely discontinue anticomplement therapy.<\/jats:p>","DOI":"10.1182\/hematology.2024000543","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:02:25Z","timestamp":1733479345000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy"],"prefix":"10.1182","volume":"2024","author":[{"given":"Anuja","family":"Java","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"7","key":"2024121115354671800_hem2024000543C1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2024121115354671800_hem2024000543C2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","article-title":"Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies","volume":"105","author":"Maisons","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"2024121115354671800_hem2024000543C3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2024121115354671800_hem2024000543C4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-072211-110606","article-title":"Defective complement inhibitory function predisposes to renal disease","volume":"64","author":"Java","year":"2013","journal-title":"Annu Rev Med"},{"key":"2024121115354671800_hem2024000543C5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","article-title":"Complement dysregulation and disease: insights from contemporary genetics","volume":"12","author":"Liszewski","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"2024121115354671800_hem2024000543C6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"2024121115354671800_hem2024000543C7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"2024121115354671800_hem2024000543C8","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti- factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2024121115354671800_hem2024000543C9","doi-asserted-by":"crossref","first-page":"607211","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2024121115354671800_hem2024000543C10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"2024121115354671800_hem2024000543C11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2013.447","article-title":"Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better","volume":"85","author":"Loirat","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"2024121115354671800_hem2024000543C12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"J\u00f3zsi","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2024121115354671800_hem2024000543C13","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2024121115354671800_hem2024000543C14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jmedgenet-2014-102498","article-title":"Factors determining penetrance in familial atypical haemolytic uraemic syndrome","volume":"51","author":"Sansbury","year":"2014","journal-title":"J Med Genet"},{"issue":"8","key":"2024121115354671800_hem2024000543C15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/nep.14304","article-title":"Characterization of patients with aHUS and associated triggers or clinical conditions: a global aHUS registry analysis","volume":"29","author":"Licht","year":"2024","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"2024121115354671800_hem2024000543C16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","article-title":"Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period","volume":"78","author":"Burwick","year":"2021","journal-title":"Hypertension"},{"issue":"15","key":"2024121115354671800_hem2024000543C17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"2024121115354671800_hem2024000543C18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2024121115354671800_hem2024000543C19","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","article-title":"Extra-renal manifestations of atypical hemolytic uremic syndrome","volume":"34","author":"Formeck","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2024121115354671800_hem2024000543C20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2024121115354671800_hem2024000543C21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"7","key":"2024121115354671800_hem2024000543C22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00467-022-05451-2","article-title":"Systematic review of atypical hemolytic uremic syndrome biomarkers","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2024121115354671800_hem2024000543C23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"2","key":"2024121115354671800_hem2024000543C24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.ackd.2019.11.003","article-title":"Peri- and post-operative evaluation and management of atypical hemolytic uremic syndrome (aHUS) in kidney transplantation","volume":"27","author":"Java","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"2024121115354671800_hem2024000543C25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ekir.2019.04.003","article-title":"A multimodality approach to assessing factor I genetic variants in atypical hemolytic uremic syndrome","volume":"4","author":"Java","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2024121115354671800_hem2024000543C26","doi-asserted-by":"crossref","first-page":"775280","DOI":"10.3389\/fmed.2021.775280","article-title":"Clinicopathologic implications of complement genetic variants in kidney transplantation","volume":"8","author":"Ren","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"22","key":"2024121115354671800_hem2024000543C27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"key":"2024121115354671800_hem2024000543C28","doi-asserted-by":"crossref","first-page":"602284","DOI":"10.3389\/fimmu.2020.602284","article-title":"Functional characterization of rare genetic variants in the N-terminus of complement factor H in aHUS, C3G, and AMD","volume":"11","author":"Wong","year":"2020","journal-title":"Front Immunol"},{"key":"2024121115354671800_hem2024000543C29","doi-asserted-by":"crossref","first-page":"789897","DOI":"10.3389\/fimmu.2021.789897","article-title":"Functional analysis of variants in complement factor I identified in age-related macular degeneration and atypical hemolytic uremic syndrome","volume":"12","author":"de Jong","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2024121115354671800_hem2024000543C30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"issue":"23","key":"2024121115354671800_hem2024000543C31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2024121115354671800_hem2024000543C32","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2024121115354671800_hem2024000543C33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"Corrigendum to \u201cThe long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"issue":"18","key":"2024121115354671800_hem2024000543C34","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024121115354671800_hem2024000543C35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00467-019-4192-7","article-title":"Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way","volume":"34","author":"Ariceta","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2024121115354671800_hem2024000543C36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"8","key":"2024121115354671800_hem2024000543C37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/ckj\/sfaa241","article-title":"Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal","volume":"14","author":"Duineveld","year":"2021","journal-title":"Clin Kidney J"},{"issue":"27","key":"2024121115354671800_hem2024000543C38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2024121115354671800_hem2024000543C39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00467-023-06120-8","article-title":"Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities","volume":"39","author":"Antonucci","year":"2024","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"2024121115354671800_hem2024000543C40","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ekir.2023.04.029","article-title":"Design and rationale of the APPELHUS phase 3 open-label study of factor B inhibitor iptacopan for atypical hemolytic uremic syndrome","volume":"8","author":"Kavanagh","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/200\/2346568\/200java.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/200\/2346568\/200java.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T14:40:15Z","timestamp":1733928015000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/200\/526220\/Atypical-hemolytic-uremic-syndrome-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000543","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}